Ixico Plc · LSE:IXI
Ixico — Ixico Plc Ord New — FY2025 Earnings Presentation
20 slides from Ixico's earnings presentation, Dec 9, 2025
Slide 1: Final Results Presentation
Final Results Presentation For the year ending 30 September 2025 December 2025
Slide 2: Nonregulated Disclaimer
Nonregulated Disclaimer This presentation is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which incl
Slide 3: IXICO – At a glance
IXICO – At a glance >80 employees (27% PhDs) 28 current studies with… The leading iCRO focussed exclusively on CNS 17 leading global pharma, biotech & diagnostics Co’s 20 years of neuroscience >1,250 imaging centres around the world utilising the IXI expertise delivering gold standard technology pla
Slide 4: IXICO – Business model
IXICO – Business model Alzheimer's Disease IXICO AI PLATFORM Imaging biomarkers Huntington's Disease Drug safety Multiple Sclerosis Patient Parkinson's Trial management Disease eligibility Other: Demyelinating IXICO EXPERTISE Drug Disorders efficacy Other: Parkinsonian Data analytics Disorders Other
Slide 5: 'Innovate Lead Scale' Strategy – Execution
'Innovate Lead Scale’ Strategy – Execution RAG FY25 investments & outcomes New AD/PD product offerings INNOVATE Deployment of next gen IXI Product differentiation TA diversification Technology expansion Disease diversification Novel IXI applications & revenues ACCELERATE REVENUE Heightened conferenc
Slide 6: 'Innovate Lead Scale' Strategy – Impact in 2025
'Innovate Lead Scale’ Strategy – Impact in 2025 £0.5m HD Validation of Positive H1 Fujirebio BBB GAP data £1.2m BBB & £3.5m HD contract IXI by HDIH update FDA clearance deal AD contract Ph3 contract £3.7m Siemens £0.5m AD & Interims £1.3m AD & capital partnership HD contract >26% T/O FA contract rai
Slide 7: 'Innovate Lead Scale' Strategy – Delivering differentiation
'Innovate Lead Scale’ Strategy – Delivering differentiation Therapeutic Area Platform progress Commercial impact • Accelerated commercial traction AD • New market segment (BBB diagnostics) • Pipeline progress PD • KOL engagement generating commercial traction • Dominant position as market leader HD
Slide 8: Therapeutic area – Market trends / IXICO impact
Therapeutic area – Market trends / IXICO impact Therapeutic Area Market trends IXICO impact • FDA approved therapy momentum (3 anti-amyloid DMTs) • Vascular biomarker algorithms • First FDA approved BBB diagnostics • GAP data partnership AD • >biomarker use • AD clinical trial wins • GLP-1 developme
Slide 9: Financials
Financials Strong revenue growth, enlarged orderbook FINAL RESULTS FY2025 | © IXICO PLC
Slide 10: FY25 Financials – growing revenues, narrowing losses
FY25 Financials – growing revenues, narrowing losses Revenues (£m) Gross Margin (%) EBITDA (£m) 6.7 6.5 49 49 5.8 47 -0.8 -1.3 -1.7 2023 2024 2025 2023 2024 2025 2023 2024 2025 ▪ £6.5m revenues ▪ 49% gross margin ▪ £1.3m EBITDA loss ▪ 13% revenue growth driven by: ▪ Increase in gross margin tracks r
Slide 11: FY25 Financials – investing to sustain growth
FY25 Financials – investing to sustain growth Cash (£m) Capital investment (£m) Net Assets (£m) 4.0 11.4 11.7 3.5 9.5 1.8 1.9 0.7 0.5 0.6 2023 2024 2025 2023 2024 2025 2023 2024 2025 ▪ £3.5m debt-free cash position ▪ £1.3m capital investment ▪ £11.7m net assets (24% growth on 2024) ▪ £3.7m net proce
Slide 12: Order book – H2-25 momentum further accelerates in Q1-26
Order book – H2-25 momentum further accelerates in Q1-26 Order Book (£m) 5.1 1.2 6.5 4.2 H2 - 2.0 H1 17.7 1.2 15.3 13.8 12.6 12.6 12.6 30-Sep-24 Revenues Client trial Trial wins 30-Sep-25 Revenues Client trial Trial wins 30-Nov-25 descopes and descopes and fx fx ▪ £17.7m of future revenues contracte
Slide 13: Order book – Diversified project mix; growth in Phase
Order book – Diversified project mix; growth in Phase 3 By project (£m) By clinical trial phase (£m) By therapeutic indication (No.) £17.7m £17.7m 28 0.8 25 25 £15.3m (3) 1.3 0.7 £13.8m 10 £15.3m 1.6 (2) 0.1 8 1.5 9 (6) 6.1 (8) £13.8m 2.9 1 2.7 1 1 6 6 5 4.8 7.4 7.6 10 10 (10) 11 5.2 2.1 1.9 30-Sep-
Slide 14: Order book – Diversified project mix; growth in Phase
Order book – Diversified project mix; growth in Phase 3 By project (£m) By clinical trial phase (£m) By therapeutic indication (No.) £17.7m £17.7m 28 0.8 25 25 £15.3m (3) 1.3 0.7 £13.8m 10 £15.3m 1.6 (2) 0.1 8 1.5 9 (6) 6.1 (8) £13.8m 2.9 1 2.7 1 1 6 6 5 4.8 7.4 7.6 10 10 (10) 11 5.2 2.1 1.9 30-Sep-
Slide 15: FY26 Growth Strategy
FY26 Growth Strategy Accelerate growth, increase company value FINAL RESULTS FY2025 | © IXICO PLC
Slide 16: Leveraging IXI – Moving beyond £10m revenues
Leveraging IXI – Moving beyond £10m revenues Revenues via multimodal strategy Market Value & Revenues to accelerate double digit growth TechBio Model Expansion of multimodal model iCRO+ Expansion of existing verticals FY25 FY26 FY27 FY28 FY29 FY30 30/09/25 30/09/26 30/09/27 30/09/28 30/09/29 30/09/3
Slide 17: FY26 Growth strategy- targeting £10m revenue in medium term
FY26 Growth strategy- targeting £10m revenue in medium term FY26 bookings expansion – transforming the order book *Estimated by Mgmt. based on bottom-up review of clinical trial start ups over a 12–18-month period (Source: GlobalData) Outcome Revenue growth | Reduced losses | Increased order book Se
Slide 18: FY26 Growth strategy- Leveraging the TechBio opportunity
FY26 Growth strategy- Leveraging the TechBio opportunity NOW GROWTH TA expansion & innovation Geographic footprint NEXT Pipeline/revenue growth Modular Flexible iCRO+ CLINICAL VALUE Scalable Platform automation for clinical trial Platform, tools & algorithms developed Faster iCRO revenue, OB validat
Slide 19: Investment case – clear transformation strategy & execution
Investment case – clear transformation strategy & execution Financial Strong revenue & OB growth performance Value creation Scientific Trusted, respected 20-year track record of expertise with loyal repeat business clients • 15%+ YoY revenue growth track record • 25%+ YoY order book growth Technolog
Slide 20: Thank you
Thank you www.ixico.com